WntResearch announces the last day for trading in BTU and the first day for trading in warrants series TO 7 and warrants series TO 8
During the period 15 – 29 January 2024, Wntresearch AB ("WntResearch" or the "Company") carried out a rights issue of units, consisting of shares and warrants series TO 7 and TO 8 (the "Rights Issue"). Through the Rights Issue, WntResearch has received approximately SEK 31.4 million before issue costs and, in the event of full exercise of all warrants issued, WntResearch may receive additional proceeds amounting to approximately SEK 26.9 million before issue costs, based on a maximum subscription price of SEK 0.12.
The Rights Issue has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and paid subscribed units (Sw. betald tecknad unit, BTU) will be replaced by ordinary shares and warrants series TO 7 and TO 8. The last day for trading with BTU on Spotlight Stock Market is 13 February 2024, and the stop date with Euroclear Sweden AB is 15 February 2024, whereafter shares and warrants will be booked in each shareholder's VP account/depository on 19 February 2024. The warrants series TO 7 will be traded with ISIN code SE0021149994 and warrants series TO 8 will be traded with ISIN SE0021150000.The first day for trading in warrants series TO 7 and TO 8 is expected to be 19 February 2024.
Through the Rights Issue, the number of shares in WntResearch increases with 448,091,572 shares, from 400,967,429 shares to 849,059,001 shares and the share capital increases, based on a quota value per share of SEK 0.04, by SEK 17,923,662.88, from SEK 16,038,697.16 to SEK 33,962,360.04. In the event of full exercise of all issued warrants series TO 7 for subscription of new shares in the Company, the number of shares will increase with additional 112,022,893 shares to a total of 961,081,894 shares and the share capital will increase by additional SEK 4,480,915.72 to SEK 38,443,275.76, based on a quota value per share of SEK 0.04. In the event of full exercise of all issued warrants series TO 8 for subscription of new shares in the Company, the number of shares will increase with additional 112,022,893 shares to a total of 1,073,104,787 shares and the share capital will increase by additional SEK 4,480,915.72 to SEK 42,924,191.48, based on a quota value per share of SEK 0.04.
Advisers
Vator Securities AB acts as financial adviser and Setterwalls Advokatbyrå AB acts as legal adviser to the Company in connection with the Rights Issue. Vator Securities AB also acts as issuer agent in connection with the Rights Issue.
For further information:
Pernilla Sandwall, CEO
E-mail: pernilla.sandwall@wntresearch.com
This information was submitted for publication, through the agency of the contact person set out above, on 8 February 2024 at 16.30 CET.
About Wntresearch AB
WntResearch is developing a completely new type of drug with the potential to improve survival in cancer without giving rise to serious side effects. Ad hoc observations from an ongoing phase 2 study in patients with colon cancer indicate that the Company's drug candidate Foxy-5 has a tumor suppressive effect already after three weeks of treatment. This means that Foxy-5 could counteract the ability of cancer cells to spread and invade healthy tissue, but also potentially eliminate cancer cells. The clinical study is now continuing with the aim of confirming these promising research findings. WntResearch then intends to establish partnerships with one or more international pharmaceutical companies ahead of the final part of the development and a global commercialization. WntResearch's shares are traded on Spotlight Stock Market. For more information, visit www.wntresearch.com.
IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in WntResearch. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for units in Wntresearch has only been made through the Prospectus that WntResearch published on 8 January 2024. The Prospectus has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and has been published on the Company's website, www.wntresearch.com. The approval of the Prospectus by the Swedish Financial Supervisory Authority shall not be regarded as an approval of the Company's shares, warrants or any other securities. This release is not a prospectus in accordance with the definition in the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in WntResearch. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety.
The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares, warrants or other securities in WntResearch have been registered, and no shares, warrants or other securities will be registered, under the United States Securities Act of 1933, as amended (the "Securities Act") or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.
Within the European Economic Area ("EEA"), no public offering of shares, warrants or other securities ("Securities") is made in other countries than Sweden. In other member states of the EU, such an offering of Securities may only be made in accordance with the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.
In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.
This press release may contain forward-looking statements which reflect the Company's current view on future events and financial and operational development. Words such as "intend", "will", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.
This information, the opinions and the forward-looking statements included in this press release are only applicable as of this date and may change without any notice thereof. WntResearch does not undertake to publish any updates or amendments of forward-looking statements, future events or similar circumstances other than what is required by appliable legislation.
Since WntResearch conducts essential services according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), certain investments in the Rights Issue may require review by the Inspectorate of Strategic Products (ISP). The Company has, in connection with the publication of the Prospectus, published more information about this on the Company's website, www.wntresearch.com.